These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

777 related articles for article (PubMed ID: 30016965)

  • 1. Lycorine inhibits glioblastoma multiforme growth through EGFR suppression.
    Shen J; Zhang T; Cheng Z; Zhu N; Wang H; Lin L; Wang Z; Yi H; Hu M
    J Exp Clin Cancer Res; 2018 Jul; 37(1):157. PubMed ID: 30016965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lycorine is a novel inhibitor of the growth and metastasis of hormone-refractory prostate cancer.
    Hu M; Peng S; He Y; Qin M; Cong X; Xing Y; Liu M; Yi Z
    Oncotarget; 2015 Jun; 6(17):15348-61. PubMed ID: 25915156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lycorine inhibits the growth and metastasis of breast cancer through the blockage of STAT3 signaling pathway.
    Wang J; Xu J; Xing G
    Acta Biochim Biophys Sin (Shanghai); 2017 Sep; 49(9):771-779. PubMed ID: 28910973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanism of lycorine in the treatment of glioblastoma based on network pharmacology and molecular docking.
    Su J; Huo M; Xu F; Ding L
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Mar; 397(3):1551-1559. PubMed ID: 37668687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
    Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S
    Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lycorine inhibits breast cancer growth and metastasis via inducing apoptosis and blocking Src/FAK-involved pathway.
    Ying X; Huang A; Xing Y; Lan L; Yi Z; He P
    Sci China Life Sci; 2017 Apr; 60(4):417-428. PubMed ID: 28251459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of molecular anti-metastasis mechanisms of lycorine in colorectal cancer by RNA-seq analysis.
    Gao L; Feng Y; Ge C; Xu X; Wang S; Li X; Zhang K; Wang C; Dai F; Xie S
    Phytomedicine; 2021 May; 85():153530. PubMed ID: 33761445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Narciclasine, a plant growth modulator, activates Rho and stress fibers in glioblastoma cells.
    Lefranc F; Sauvage S; Van Goietsenoven G; Mégalizzi V; Lamoral-Theys D; Debeir O; Spiegl-Kreinecker S; Berger W; Mathieu V; Decaestecker C; Kiss R
    Mol Cancer Ther; 2009 Jul; 8(7):1739-50. PubMed ID: 19531573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual blockade of EGFR and PI3K signaling pathways offers a therapeutic strategy for glioblastoma.
    Guo T; Wu C; Zhang J; Yu J; Li G; Jiang H; Zhang X; Yu R; Liu X
    Cell Commun Signal; 2023 Dec; 21(1):363. PubMed ID: 38115126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic effects of the immune checkpoint inhibitor CTLA-4 combined with the growth inhibitor lycorine in a mouse model of renal cell carcinoma.
    Li X; Xu P; Wang C; Xu N; Xu A; Xu Y; Sadahira T; Araki M; Wada K; Matsuura E; Watanabe M; Zheng J; Sun P; Huang P; Nasu Y; Liu C
    Oncotarget; 2017 Mar; 8(13):21177-21186. PubMed ID: 28416753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lycorine inhibits melanoma cell migration and metastasis mainly through reducing intracellular levels of β-catenin and matrix metallopeptidase 9.
    Zhang P; Zhang M; Yu D; Liu W; Hu L; Zhang B; Zhou Q; Cao Z
    J Cell Physiol; 2019 Jul; 234(7):10566-10575. PubMed ID: 30565685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crizotinib and erlotinib inhibits growth of c-Met
    Goodwin CR; Rath P; Oyinlade O; Lopez H; Mughal S; Xia S; Li Y; Kaur H; Zhou X; Ahmed AK; Ho S; Olivi A; Lal B
    Clin Neurol Neurosurg; 2018 Aug; 171():26-33. PubMed ID: 29803091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lycorine improves peripheral nerve function by promoting Schwann cell autophagy via AMPK pathway activation and MMP9 downregulation in diabetic peripheral neuropathy.
    Yuan Q; Zhang X; Wei W; Zhao J; Wu Y; Zhao S; Zhu L; Wang P; Hao J
    Pharmacol Res; 2022 Jan; 175():105985. PubMed ID: 34863821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lycorine inhibits lipopolysaccharide-induced iNOS and COX-2 up-regulation in RAW264.7 cells through suppressing P38 and STATs activation and increases the survival rate of mice after LPS challenge.
    Kang J; Zhang Y; Cao X; Fan J; Li G; Wang Q; Diao Y; Zhao Z; Luo L; Yin Z
    Int Immunopharmacol; 2012 Jan; 12(1):249-56. PubMed ID: 22155741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lycorine, the main phenanthridine Amaryllidaceae alkaloid, exhibits significant antitumor activity in cancer cells that display resistance to proapoptotic stimuli: an investigation of structure-activity relationship and mechanistic insight.
    Lamoral-Theys D; Andolfi A; Van Goietsenoven G; Cimmino A; Le Calvé B; Wauthoz N; Mégalizzi V; Gras T; Bruyère C; Dubois J; Mathieu V; Kornienko A; Kiss R; Evidente A
    J Med Chem; 2009 Oct; 52(20):6244-56. PubMed ID: 19788245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition.
    Clark PA; Iida M; Treisman DM; Kalluri H; Ezhilan S; Zorniak M; Wheeler DL; Kuo JS
    Neoplasia; 2012 May; 14(5):420-8. PubMed ID: 22745588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma.
    Zheng Q; Han L; Dong Y; Tian J; Huang W; Liu Z; Jia X; Jiang T; Zhang J; Li X; Kang C; Ren H
    Neuro Oncol; 2014 Sep; 16(9):1229-43. PubMed ID: 24861878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
    Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
    J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.